Topical Creams for TMJ Pain
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores the effectiveness of two topical creams in relieving jaw joint pain (TMJ arthralgia). Participants will use either a 2.5% hydrocortisone cream (a corticosteroid) or a 1% diclofenac cream (a nonsteroidal anti-inflammatory drug) to determine which better reduces pain and improves jaw movement, while monitoring for side effects. The trial suits individuals who have experienced jaw pain for at least three days and are not currently using or have recently used steroids. As a Phase 3 trial, it represents the final step before FDA approval, allowing participants to contribute to the potential availability of a new treatment.
Will I have to stop taking my current medications?
The trial requires that you stop taking any steroids and muscle relaxants before participating. You can start muscle relaxants again after the study is complete.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
A previous study found that hydrocortisone 2.5% cream was generally well-tolerated when applied to the skin. It is commonly used for conditions like eczema and insect bites to relieve itching and swelling. Some individuals might notice minor side effects such as redness or irritation at the application site, but these are usually mild.
Research has shown that diclofenac 1% cream is also generally well-tolerated. It is often used to treat joint pain from arthritis. Some individuals might experience mild side effects like redness or dry skin at the application site.
Both treatments have been used safely for other conditions, so their safety is well-understood. However, it is important to remember that everyone's body reacts differently, and what works well for one person might not suit another.12345Why are researchers excited about this trial's treatments?
Researchers are excited about these treatments for TMJ pain because they offer non-invasive, topical solutions compared to standard oral medications or injections. Diclofenac 1% cream targets inflammation directly at the site, potentially reducing side effects associated with oral NSAIDs. Hydrocortisone 2.5% cream provides a steroid-based approach, which can be effective in reducing inflammation and pain locally without systemic exposure. These creams provide a targeted, easy-to-apply option that could be more comfortable and accessible for patients seeking relief from TMJ pain.
What evidence suggests that this trial's treatments could be effective for TMJ pain?
This trial will compare two topical creams for TMJ pain. Research has shown that a 2.5% hydrocortisone cream, which participants in one arm of this trial may receive, can reduce pain and swelling in joints by calming the body's immune system, potentially easing jaw pain for those with TMJ arthralgia.
In another arm of this trial, participants may receive a 1% diclofenac cream. Studies have found that diclofenac, an NSAID, effectively reduces TMJ pain by lowering swelling and pain.
Both treatments have shown promise, with diclofenac often significantly reducing pain compared to placebos. This evidence suggests that both creams could be effective options for managing TMJ pain.678910Are You a Good Fit for This Trial?
This trial is for individuals experiencing pain in at least one temporomandibular joint (TMJ) for a minimum of three days. It's not suitable for those with systemic pain conditions, past steroid reactions, current or recent steroid use, or those who've started using muscle relaxants or a new night guard around the study period.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants apply topical cream four times a day for 21 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Diclofenac 1% topical
- Hydrocortisone 2.5%
Diclofenac 1% topical is already approved in European Union, United States, Canada, Japan for the following indications:
- Pain relief
- Inflammation
- Arthritis
- Musculoskeletal disorders
- Pain relief
- Osteoarthritis
- Rheumatoid arthritis
- Ankylosing spondylitis
- Pain relief
- Inflammation
- Arthritis
- Musculoskeletal disorders
- Pain relief
- Inflammation
- Arthritis
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of the Pacific
Lead Sponsor